Cargando…
MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate
Control of micrometastatic pancreatic cancer remains a major objective in pancreatic cancer treatment. The overexpression of MUC1 mucin plays an important role in cancer metastasis. The aim of this study was to detect the expression of MUC1 in human primary tumour tissues and three pancreatic cancer...
Autores principales: | Qu, C F, Li, Y, Song, Y J, Rizvi, S M A, Raja, C, Zhang, D, Samra, J, Smith, R, Perkins, A C, Apostolidis, C, Allen, B J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409789/ https://www.ncbi.nlm.nih.gov/pubmed/15599383 http://dx.doi.org/10.1038/sj.bjc.6602232 |
Ejemplares similares
-
Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma
por: Hull, Ashleigh, et al.
Publicado: (2022) -
(213)Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model
por: Li, Y, et al.
Publicado: (2002) -
Preclinical studies of targeted α therapy for breast cancer using (213)Bi-labelled-plasminogen activator inhibitor type 2
por: Allen, B J, et al.
Publicado: (2003) -
Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells
por: Moniaux, N, et al.
Publicado: (2007) -
An anti-MUC1-antibody–interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells
por: Heuser, C, et al.
Publicado: (2003)